Anteris Technologies Files 8-K

TL;DR

Anteris Tech filed an 8-K on Nov 17, 2025, with Reg FD disclosures and financials.

AI Summary

Anteris Technologies Global Corp. filed an 8-K on November 17, 2025, reporting a Regulation FD Disclosure and Financial Statements and Exhibits. The company, incorporated in Delaware, operates in the orthopedic, prosthetic & surgical appliances & supplies industry. Its principal executive offices are located in Eagan, MN, with a phone number of 651-493-0606.

Why It Matters

This filing provides updates on Anteris Technologies Global Corp.'s regulatory disclosures and financial statements, which are important for investors to assess the company's current standing and future prospects.

Risk Assessment

Risk Level: low — This is a routine filing of an 8-K, indicating standard corporate reporting rather than a significant event.

Key Numbers

• 001-42437 — SEC File Number (Identifies the company's filing with the SEC.)
• 99-1407174 — IRS Employer Identification No. (Tax identification number for the company.)

Key Players & Entities

• Anteris Technologies Global Corp. (company) — Registrant
• November 17, 2025 (date) — Date of Report
• Delaware (jurisdiction) — State of Incorporation
• 3842 (industry_code) — Standard Industrial Classification
• Eagan, MN (location) — Business Address City, State
• 651-493-0606 (phone_number) — Business Phone

FAQ

Key Financial Figures

• $0.0001 — ich registered Common Stock, par value $0.0001 per share AVR The Nasdaq Global Mar

Filing Documents

• ef20059387_8k.htm (8-K) — 32KB
• ef20059387_ex99-1.htm (EX-99.1) — 30KB
• image00001.jpg (GRAPHIC) — 4KB
• image00002.jpg (GRAPHIC) — 1KB
• 0001140361-25-042395.txt ( ) — 206KB
• avr-20251117.xsd (EX-101.SCH) — 4KB
• avr-20251117_lab.xml (EX-101.LAB) — 22KB
• avr-20251117_pre.xml (EX-101.PRE) — 16KB
• ef20059387_8k_htm.xml (XML) — 4KB

01

Item 7.01. Regulation FD Disclosure On November 16, 2025 (November 17, 2025 AEDT), Anteris Technologies Global Corp. (the "Company") issued an ASX Announcement and on November 17, 2025 issued a press release presenting the 30-day clinical outcomes for the DurAVR Transcatheter Heart Valve (THV) in one hundred severe aortic stenosis patients with small aortic annuli. The information in this Current Report on Form 8-K, including the exhibit attached hereto, is being furnished and shall not be deemed to be filed for the purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act"), or incorporated by reference into any filing under the Securities Act of 1933 (the "Securities Act") or the Exchange Act, unless such subsequent filing specifically references this Current Report on Form 8-K.

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits. The following exhibits are filed with this Current Report on Form 8-K: Exhibit No. Description 99.1 ASX announcement: Anteris Technologies Presents Data from 100 DurAVR THV Patients at PCR London Valves 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Anteris Technologies Global Corp. Date: November 17, 2025 By: /s/ Wayne Paterson Name: Wayne Paterson Title: Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR